197 related articles for article (PubMed ID: 23403818)
1. NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y
Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
[TBL] [Abstract][Full Text] [Related]
3. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
[TBL] [Abstract][Full Text] [Related]
4. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
6. Urine antibody against human cancer antigen NY-ESO-1.
Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
[TBL] [Abstract][Full Text] [Related]
9. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma].
Wu XJ; Wang Y; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):252-6. PubMed ID: 15968313
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A
Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728
[TBL] [Abstract][Full Text] [Related]
12. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.
Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y;
Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491
[TBL] [Abstract][Full Text] [Related]
13. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
16. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
17. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
[TBL] [Abstract][Full Text] [Related]
18. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
19. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
[TBL] [Abstract][Full Text] [Related]
20. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
